Versartis Long-Term Safety Study of Somavaratan

Stopped The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved

Conditions

• Pediatric Growth Hormone Deficiency

Interventions

• DRUG: somavaratan

Sponsor

Versartis Inc.